secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2022-07-07T23:59:59+00:00
Accession:  0001193125-22-189446
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Aeglea BioTherapeutics director Sandesh Mahatme resigns, effective July 8, 2022
-------------------------------------------------------------------------------

- Sandesh Mahatme resigned as Class I director effective July 8, 2022.
- Resignation not due to any disagreement with company operations, policies, or practices.
- No replacement named at this time.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000119312522189446/0001193125-22-189446-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000119312522189446/d274196d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-189446

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer